These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8794900)

  • 1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
    Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and conformational preference of novel 8-fluoroanthracyclines.
    Lombardi P; Animati F; Cipollone A; Giannini G; Monteagudo E; Arcamone F
    Acta Biochim Pol; 1995; 42(4):433-44. PubMed ID: 8852334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.
    Capranico G; Supino R; Binaschi M; Capolongo L; Grandi M; Suarato A; Zunino F
    Mol Pharmacol; 1994 May; 45(5):908-15. PubMed ID: 8190107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
    Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
    Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
    Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
    Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F; Capranico G
    Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
    Capranico G; Butelli E; Zunino F
    Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
    Arcamone F
    Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
    Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
    Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
    Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
    Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
    J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
    Capranico G; Soranzo C; Zunino F
    Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
    Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.
    Binaschi M; Farinosi R; Borgnetto ME; Capranico G
    Cancer Res; 2000 Jul; 60(14):3770-6. PubMed ID: 10919649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs.
    Spadari S; Pedrali-Noy G; Focher F; Montecucco A; Bordoni T; Geroni C; Giuliani FC; Ventrella G; Arcamone F; Ciarrocchi G
    Anticancer Res; 1986; 6(5):935-40. PubMed ID: 3026237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
    Pratesi G; De Cesare M; Caserini C; Perego P; Dal Bo L; Polizzi D; Supino R; Bigioni M; Manzini S; Iafrate E; Salvatore C; Casazza A; Arcamone F; Zunino F
    Clin Cancer Res; 1998 Nov; 4(11):2833-9. PubMed ID: 9829750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.